Chiayi Chang Gung Memorial Hospital

Endoscopic Decompression Versus Fusion for Degenerative Lumbar Spondylolisthesis: A Structured Debate and International Practice Patterns

Degenerative lumbar spondylolisthesis (DLS) combines neural compression with a variable mechanical phenotype, creating uncertainty over whether decompression alone is sufficient or fusion is required. Over the last few decades, endoscopic spine surgery (ESS) has opened new avenue...

Postoperative hemorrhage and perioperative outcomes in single-port versus multi-port transoral robotic surgery for upper airway disease

The integration of transoral robotic surgery (TORS) has catalyzed a paradigm shift in the management of upper airway pathologies; however, the multifaceted operational distinctions between next-generation single-port (SP) platforms and conventional multi-port systems warrant comp...

Clinical Implications of the Novel Genetic Polymorphism Associated With Retinal Vein Occlusion: The East Asian GWAS Survey in a Single-Center Taiwanese Cohort

Purpose: To explore the single-nucleotide polymorphic features in an East Asian cohort of retinal venous occlusion (RVO) patients, to map pathogenic genes, and to analyze potential pathophysiological associations. Methods: This was a cross-sectional monocentric cohort study invol...

Clinical Safety Awareness and Self-Efficacy in MRI Safety Practice Among Nursing Professionals: A Cross-Sectional Study

Purpose The purpose was to examine the relationships among MRI safety knowledge, clinical safety awareness, and self-efficacy in MRI safety practice among nursing professionals and to identify the factors most strongly associated with self-efficacy. Methods A cross-sectional surv...

Ociperlimab and tislelizumab in advanced esophageal squamous cell carcinoma (AdvanTIG-203): a phase II study

Patients with esophageal squamous cell carcinoma (ESCC) have an unmet need for new therapies that improve survival. In this phase II trial, patients received ociperlimab and tislelizumab (A) or placebo and tislelizumab (B) (NCT04732494). The primary endpoint was objective respons...